|

Olaparib; 177Lu-DOTATATE Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Fundación de investigación HM1

Indications

  • Adrenal Tumours1
  • Neuroendocrine Tumours (NET)1
  • High Grade Gliomas1
  • Meningioma1
  • Solid Tumor Cancer1

Other1 trial

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.